Neurogenic inflammation and asthma.

Abstract

Over the past number of decades there has been considerable interest in the role of neurogenic inflammation in asthma with the identification of many biologically active neuropeptides in the lung. Whilst there is convincing evidence of neurogenic inflammation in various animal models of asthma, the evidence in humans is less clear and replicating the experimental approaches in humans has proven difficult with different studies producing conflicting results. In terms of human studies, research has focused on whether pro-inflammatory neuropeptides are elevated in the asthmatic airway, and if so, what their functional effects are. There have also been studies to assess the efficacy of tachykinin receptor antagonists in improving indices of asthma control. Information to date would suggest that neuropeptides are present in human airways and are possibly upregulated in asthma, but this effect does not appear to be specific and may occur in other inflammatory airways conditions (chronic obstructive pulmonary disease (COPD) and smoking). At present there is insufficient evidence to suggest that tachykinin receptor antagonists confer any additional benefit over inhaled corticosteroid regimes for asthmatic patients.

• Authors: Claire A Butler, Liam G Heaney
• Journal: Inflammation & allergy drug targets (Inflamm Allergy Drug Targets) Vol. 6 Issue 2 Pg. 127-32 (Jun 2007) ISSN: 1871-5281 [Print] United Arab Emirates
• PMID: 17692036 (Publication Type: Journal Article, Review)

Chemical References

• Neuropeptides
• Receptors, Tachykinin

Topics

• Animals
• Asthma (complications, drug therapy, metabolism)
• Clinical Trials as Topic
• Humans
• Neurogenic Inflammation (complications, drug therapy, metabolism)
• Neuropeptides (antagonists & inhibitors, metabolism)
• Receptors, Tachykinin (antagonists & inhibitors, metabolism)
• Treatment Outcome